AnaptysBio (ANAB) vs Kailera Therapeutics (KLRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Kailera Therapeutics is the larger company by market cap ($1.37 billion vs $1.36 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | KLRA |
|---|---|---|
| Share price | $45.65 | $10.53 |
| Market cap | $1.36B | $1.37B |
| 1-day change | -4.68% | -2.77% |
| 5-year return | +138.84% | — |
| Forward P/E | 9.01 | — |
| EPS (TTM) | $-0.96 | $-4.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $28.23 |
| 52-week low | $20.18 | $9.85 |
| Distance from 52-week high | -36.91% | -62.70% |
| Average volume | 569.55K | 843.68K |
| Shares outstanding | 29.90M | 129.64M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ANAB vs KLRA FAQ
Which is bigger, AnaptysBio or Kailera Therapeutics?
Kailera Therapeutics (KLRA) is larger, with a market capitalization of $1.37B compared with $1.36B for AnaptysBio (ANAB).
Are AnaptysBio and Kailera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.